Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
HealthPartners Institute
With
Amylin Pharmaceuticals, LLC.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
18 years or older
type 2 diabetes
A1c 7.1 - 11
BMI 25 - 45
stable weight for 3 months before screening
fasting glucose \< 280 at screening
stable dose of metformin for at least 2 months before screening
not being treated with or on a stable dose of hormone replacement therapy, oral contraceptives, anti-hypertensive agents, lipid lowering agents, thyroid replacement therapy, anti-depressants, drugs known to affect body weight
male or female, non-lactating, non-pregnant and willing to use birth control
lab values that are not clinically significant at screening
physical exam and ECG that are not clinically significant at screening
able to read, understand, and sign consent form
You may not be if
liver disease
renal disease
cardiovascular disease
gastroparesis
cancer within 5 years of screening
macular edema
chronic infections
drug or alcohol abuse
fasting triglycerides \> or = 600 at screening
previous exposure to exenatide LAR
has donated blood within 60 days of screening or is planning to donate during the study
has had a major surgery or blood transfusion within 2 months before screening
is currently being treated or is expecting to be treated with Byetta, Januvia, SU, TZD, GLP-1 analog, alpha-glucosidase inhibitor, meglitinide, nateglinide, symlin, insulin, systemic corticosteroids, lopid or rifampin
has received an investigational drug within 1 month before screening
has allergies or hypersensitivity to any component of the study drug
has previously had an adverse event related to TZD or Januvia
is an immediate family member of the study sight or directly affiliated
is employed by Amylin, Lilly or Alkermes
Clareo Health | Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control
